Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co Announces Positive Results For Ramucirumab As Single Agent In Phase III Gastric Cancer Trial


Monday, 15 Oct 2012 08:00am EDT 

Eli Lilly And Co announced the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab. The REGARD trial compared ramucirumab and supportive care to placebo and supportive care as a second-line treatment in patients with metastatic gastric and gastroesophageal junction cancers. The frequent adverse reaction (any grade) occurring at a higher rate on the ramucirumab arm was hypertension (12%). Other adverse reactions (>5%) occurring at a higher rate on the ramucirumab arm compared to the placebo arm were diarrhea and headache. Lilly plans to present data from the REGARD trial at an upcoming scientific meeting and will discuss submission plans with regulatory authorities. 

Company Quote

62.46
0.43 +0.69%
1:39pm EDT